A Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of AB-1009 in Adult Participants With Late Onset Pompe Disease (LOPD)
Latest Information Update: 27 Feb 2026
At a glance
- Drugs AB 1009 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Acronyms PROGRESS-GT LOPD
- Sponsors Asklepios BioPharmaceutical
Most Recent Events
- 08 Jan 2026 According to AskBio media release, FDA has accepted the IND for this Phase 1/Phase 2 trial. The company anticipates recruiting its first patient in early 2026.
- 07 Jan 2026 Planned initiation date changed from 1 Dec 2025 to 1 Jan 2026.
- 07 Jan 2026 Status changed from not yet recruiting to recruiting.